<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1028-4818</journal-id>
<journal-title><![CDATA[Multimed]]></journal-title>
<abbrev-journal-title><![CDATA[Multimed]]></abbrev-journal-title>
<issn>1028-4818</issn>
<publisher>
<publisher-name><![CDATA[Centro Provincial de Información de Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1028-48182022000300004</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores de riesgo de cardiotoxicidad precoz por quimioterapia en pacientes con cáncer de mama]]></article-title>
<article-title xml:lang="en"><![CDATA[Risk factors for early cardiotoxicity due to chemotherapy in patients with breast cancer]]></article-title>
<article-title xml:lang="pt"><![CDATA[Fatores de risco para cardiotoxicidade precoce por quimioterapia em pacientes com câncer de mama]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Domínguez]]></surname>
<given-names><![CDATA[Julio Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Peña]]></surname>
<given-names><![CDATA[Marian Maité]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez Reyes]]></surname>
<given-names><![CDATA[Maidelín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leblanch Pérez]]></surname>
<given-names><![CDATA[Lisett]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Oliva]]></surname>
<given-names><![CDATA[Alberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas de Granma Hospital General Provincial Carlos Manuel de Céspedes ]]></institution>
<addr-line><![CDATA[Bayamo Granma]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>26</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1028-48182022000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1028-48182022000300004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1028-48182022000300004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  la quimioterapia triplica el riesgo de toxicidad miocárdica. Junto con las segundas neoplasias, es la causa más frecuente de mortalidad en pacientes con cáncer de mama con larga supervivencia.  Objetivo:  identificar los factores de riesgo de cardiotoxicidad precoz por quimioterapia en pacientes con cáncer de mama  Métodos:  se realizó un estudio longitudinal prospectivo de cohorte única, con 224 pacientes portadoras de cáncer de mama en tratamiento con quimioterapia seguidas en consulta de cardio-oncologíade la policlínica de especialidades del Hospital Provincial General &#8220;Carlos Manuel de Céspedes&#8221;, Bayamo, Granma, Cuba, en el periodo comprendido entre 15 de enero de 2019 a 23 marzo de 2021. Los predictores independientes de cardiotoxicidad se obtuvieron usando regresión logística multivariable.  Resultados:  la prevalencia de cardiotoxicidad fue de 19,2 % con edad media de 60,4 años, desviación estándar 12,7; hipertensión arterial, dislipidemia y otros marcadores de riesgo para enfermedades cardiovasculares como diabetes mellitus (riesgo relativo 2,8), cardiopatía hipertensiva (riesgo relativo 7,8), hipertrofia ventricular izquierda (riesgo relativo 3,3)y grasa epicárdica mayor de 6 mm, fueron variables relacionadas significativamente al riesgo de cardiotoxicidad.  Conclusiones:  cardiopatía hipertensiva, hipertrofia ventricular izquierda, diabetes mellitus, edad igual o mayor de 65 años y dislipidemia, incrementaron el riesgo de aparición de cardiotoxicidad y se relacionaron significativamente con ella, por tanto, resultaron ser factores de riesgo con influencia independiente sobre la cardiotoxicidad. Los resultados obtenidos nos permiten proyectar estudios de predicción de desarrollo y reversibilidad de cardiotoxicidad en pacientes de alto riesgo que reciban tratamientos cardioprotectores.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: chemotherapy triples the risk of myocardial toxicity. Along with second neoplasms, it is the most frequent cause of mortality in long-surviving breast cancer patients.  Objective:  to identify the risk factors for early cardiotoxicity due to chemotherapy in patients with breast cancer.  Methods: a prospective longitudinal study of a single cohort was carried out, with 224 patients with breast cancer undergoing chemotherapy treatment followed up in the cardio-oncology consultation of the specialties polyclinic at the General Provincial Hospital "Carlos Manuel de Céspedes." Bayamo. Granma, Cuba in the period from January 15, 2019 to March 23, 2021. Independent predictors of cardiotoxicity were obtained using multivariate logistic regression.  Results:  the prevalence of cardiotoxicity was 19.2% with a mean age of 60.4 years, standard deviation 12.7; arterial hypertension, dyslipidemia and other risk markers for cardiovascular diseases such as diabetes mellitus (relative risk 2.8), hypertensive heart disease (relative risk 7.8), left ventricular hypertrophy (relative risk 3.3) and epicardial fat greater than 6 mm, were variables significantly related to the risk of cardiotoxicity.  Conclusions: hypertensive heart disease left ventricular hypertrophy, Diabetes Mellitus, age &#8805;65 years and dyslipidemia increased the risk of cardiotoxicity and were significantly related to it, therefore, they turned out to be risk factors with independent influence on cardiotoxicity. The results obtained allow us to plan studies to predict the development and reversibility of cardiotoxicity in high-risk patients receiving cardioprotective treatments.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução:  a quimioterapia triplica o risco de toxicidade miocárdica. Juntamente com as segundas neoplasias, é a causa mais frequente de mortalidade em pacientes com câncer de mama de longa sobrevida.  Objetivo:  identificar os fatores de risco para cardiotoxicidade precoce por quimioterapia em pacientes com câncer de mama.  Métodos: foi realizado um estudo longitudinal prospectivo de coorte única, com 224 pacientes com câncer de mama em tratamento com quimioterapia acompanhadas na consulta de cardio-oncologia da policlínica de especialidades do Hospital Geral Provincial "Carlos Manuel de Céspedes", Bayamo, Granma, Cuba, no período de 15 de janeiro de 2019 a 23 de março de 2021. Os preditores independentes de cardiotoxicidade foram obtidos por meio de regressão logística multivariada.  Resultados:  a prevalência de cardiotoxicidade foi de 19,2% com média de idade de 60,4 anos, desvio padrão de 12,7; hipertensão arterial, dislipidemia e outros marcadores de risco para doenças cardiovasculares como diabetes mellitus (risco relativo 2,8), cardiopatia hipertensiva (risco relativo 7,8), hipertrofia ventricular esquerda (risco relativo 3,3) e gordura epicárdica maior que 6 mm, foram variáveis &#8203;&#8203;significativamente relacionadas ao risco de cardiotoxicidade.  Conclusões: cardiopatia hipertensiva, hipertrofia ventricular esquerda, diabetes mellitus, idade &#8805;65 anos e dislipidemia aumentaram o risco de cardiotoxicidade e estiveram significativamente relacionados a ela, portanto, revelaram-se fatores de risco com influencia independente na cardiotoxicidade. Os resultados obtidos permitem planejar estudos para prever o desenvolvimento e a reversibilidade da cardiotoxicidade em pacientes de alto risco recebendo tratamentos cardioprotetores.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cardio-oncología]]></kwd>
<kwd lng="es"><![CDATA[Cardiotoxicidad]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="es"><![CDATA[Insuficiencia cardiaca]]></kwd>
<kwd lng="en"><![CDATA[Cardio-oncology]]></kwd>
<kwd lng="en"><![CDATA[Cardiotoxicity]]></kwd>
<kwd lng="en"><![CDATA[Chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[Heart failure]]></kwd>
<kwd lng="pt"><![CDATA[Cardio-oncologia]]></kwd>
<kwd lng="pt"><![CDATA[Cardiotoxicidade]]></kwd>
<kwd lng="pt"><![CDATA[Quimioterapia]]></kwd>
<kwd lng="pt"><![CDATA[Insuficiência cardíaca]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herrmann]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lenihan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Armenian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Blaes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cardinale]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2022</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>280-99</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lancellotti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez Muñoz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aboyans]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Asteggiano]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Galderisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>2768-801</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Okwuosa]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Scarabelli]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Moudgil]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2017</year>
<volume>70</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2552-65</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dent]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
</person-group>
<source><![CDATA[Practical Cardio-Oncology]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Estados Unidos ]]></publisher-loc>
<publisher-name><![CDATA[CCR Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tilemann]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Heckmann]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Katus]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Lehmann]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome]]></article-title>
<source><![CDATA[Clin Res Cardiol]]></source>
<year>2018</year>
<volume>107</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>271-80</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armenian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predicting and Preventing Anthracycline-Related Cardiotoxicity]]></article-title>
<source><![CDATA[Am Soc Clin Oncol Educ Book]]></source>
<year>2018</year>
<volume>38</volume>
<page-range>3-12</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>Cuba</collab>
<source><![CDATA[Anuario Estadístico de Cuba.]]></source>
<year>2019</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[ONEI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cairo Sáez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Batista Hernández]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Peñate Tamayo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[de la Torre Santos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación cardiaca de pacientes con cáncer de mama tratadas con antraciclinas]]></article-title>
<source><![CDATA[Rev Cuban Cardiol Cir Cardiovas]]></source>
<year>2017</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedraza Rodríguez]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[González Velázquez]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Rodríguez]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factores asociados a la cardiotoxicidad inducida por antraciclinas en pacientes con cáncer de mama]]></article-title>
<source><![CDATA[Univ Méd Pinareña]]></source>
<year>2020</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e383-e94</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Banke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fosbol]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Ewertz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Videbæk]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Poulsen]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab]]></article-title>
<source><![CDATA[JACC Heart Fail]]></source>
<year>2019</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>217-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xinqiang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Yun]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wendi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.]]></article-title>
<source><![CDATA[npj Precision Oncology]]></source>
<year>2017</year>
<numero>1</numero>
<issue>1</issue>
<page-range>31-52</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales Yera]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Triana Díaz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiotoxicidad inducida por quimioterapia]]></article-title>
<source><![CDATA[Cor Salud]]></source>
<year>2018</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-77</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cardinale]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ciceri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Latini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Franzosi]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Sandri]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Civelli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anthracycline induced cardiotoxicity A multi-center randomized trial comparing two strategies for guiding prevention with enalapril: The international cardio-oncology society one trial.]]></article-title>
<source><![CDATA[Eur J Cancer. May]]></source>
<year>2018</year>
<volume>94</volume>
<page-range>126-37</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menna]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Salvatorelli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary prevention strategies for anthracycline cardiotoxicity: A brief overview]]></article-title>
<source><![CDATA[Chemotherapy]]></source>
<year>2017</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>159-68</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armenian]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Lacchetti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carver]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Constine]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Denduluri]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2017</year>
<volume>35</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>893-911</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cortés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[de Mattos Arruda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bellet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Saura]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>897-902</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prohias Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Luperon Loforte]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez López]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Claro Valdés]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Servicio de Cardiooncología en un Hospital Terciario: Experiencia del Hospital Hermanos Ameijeiras]]></article-title>
<source><![CDATA[Rev Cuban Cardiol Cir Cardiovas]]></source>
<year>2020</year>
<volume>26</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guha]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fradley]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Dent]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Weintraub]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Lustberg]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2022</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>300-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dorantes Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bazán Milián]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repolarización ventricular en la terapia oncológica]]></article-title>
<source><![CDATA[Cor Salud]]></source>
<year>2019</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>146-52</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curigliano]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lenihan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fradley]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ganatra]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barac]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Blaes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations: Annals of Oncology.]]></article-title>
<source><![CDATA[Ann. Oncol]]></source>
<year>2020</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>171-90</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
